Subscribe to RSS - BioScrip

BioScrip

Turnaround king?

Daniel Greenleaf rolls up his sleevs
 - 
11/23/2016

Daniel Greenleaf is in a familiar position. The new president and CEO of BioScrip is tasked with turning around an underperforming home infusion company, which he did with both Coram and, more recently, with Home Solutions.

BioScrip ‘took its eye off the ball’

 - 
11/11/2016

DENVER – With revenues at BioScrip sliding again in the third quarter, new President and CEO Daniel Greenleaf didn’t mince words on a recent earnings call.

In brief: Contract supplier pays $12M, CMS revises enrollment application

 - 
09/09/2016

NEWARK, N.J. – U.S. Healthcare Supply, a national contract supplier for mail-order diabetes supplies, and two of its executives have agreed to pay the government more than $12.2 million to resolve allegations that they violated the False Claims Act.

BioScrip, Home Solutions tweak deal

 - 
09/06/2016

DENVER – The price tag for BioScrip’s acquisition of Home Solutions has dropped from $85 million to $75 million, according to news reports.

BioScrip completes offering

 - 
06/22/2016

DENVER – BioScrip has completed a public offering of common stock, netting approximately $83.15 million.

BioScrip makes buy, announces public offering

 - 
06/17/2016

DENVER – BioScrip, a provider of infusion and homecare management solutions, has entered into an agreement to buy the business of HS Infusion Holdings.

BioScrip makes buy, announces public offering

 - 
06/14/2016

DENVER – BioScrip, a provider of infusion and homecare management solutions, has entered into an agreement to buy the business of HS Infusion Holdings.

BioScrip reports loss in revenues

 - 
05/06/2016

DENVER – BioScrip reported net revenues of $238.5 million for the first quarter of 2016, compared to $244.4 million for the same period a year ago, a decrease of 2.4%. Adjusted EBITDA was $7.4 millionvs. $4.9 million.

In brief: OIG targets orthotics and vents, Rep. Tipton throws support behind rural providers

 - 
11/06/2015

WASHINGTON – Orthotics and vents are among the HME that the Office of Inspector General plans to focus on in fiscal year 2016, according to a work plan published week.

BioScrip shows progress

 - 
11/04/2015

ELMSFORD, N.Y. – BioScrip today reported third quarter revenues from continuing operations of $247.3 million, a 6.8% increase over the same period last year. Gross profit was $63.1 million, a 3.9% increase, and net loss was $24.2 million, the company reported.

Pages